КЛИНИКО-ЭКОНОМИЧЕСКИЙ АНАЛИЗ ЛЕКАРСТВЕННОЙТЕРАПИИ РЕВМАТОИДНОГО АРТРИТА:ВАЖНОСТЬ ПРОБЛЕМЫ, НЕРЕШЕННЫЕ ЗАДАЧИ

1. <div><p>&lt;http://ru.wikipedia.org&gt;</p><p>Hardin G. The tragedy of the commons. The population problem has no technical solution; it requires a fundamental extension in mortality. Science 1968;162:1243-8.</p><p>Granata A.V., Hillman A.L. Competing practice guidelines: using cost-effectiveness analysis to make optimal decision. Ann Intern Med 1998;128:56-63. 4.</p><p>Воробьев П.А. Клинико-экономические исследования. Общие положения. Отраслевой стандарт (OCT 91500.14.0001-2002).</p><p>Scott D., Koshaba B., Choy E. Limited correlation between the НAQ and EuroQol in rheumatoid arthritis: questionalble validity of deriving quality adjusted life years from HAQ. Ann Rheum Dis 2007;66:1534-7.</p><p>Mark D.B., Simons Т.А. Fundamentals of economic analysis. Am Heart J 1999;137(5):38-40.</p><p>Torrance G. Measurement of health state utilities for economic appraisal. J Health Econ 1986;5:1-30. 9.</p><p>Investigating Health and Health Services - Research Methods in Health. 4. Costing health services: health economics/with Ian Rees Jones. Buckingham, Philadelphia, Open University Press, 1997; p. 79-98.</p><p>Witney A.G., Treharne G., Tavakoli M. et al. The relationship of medical, demographic and psychosocial factors to direct and indirect health utility instruments in rheumatoid arthritis. Rheumatology 2006;45:975-81.</p><p>Kobelt G., Eberhardt K., Geborek P. TNF-inhibitors in the treatment of rheumatoid arthritis in clinical practice: cost and outcomas in a follow-up study of patients with RA treated with etanercept or infliximab in southern Sweden. Ann Rheum Dis 2004;63:4-10.</p><p>Kobelt G., Lingren P., Lindrath Y. et al. Modelling the effect of function and disease activity on cost and quality of life in rheumatoid arthritis. Rheumatology (Oxford) 2005;44:1169-75.</p><p>Marra C.A., Marion S.A., Guh D.P. et al. Not all «quality-adjusted life years» are equal. J Clin Epidemiol 2007;60:616-24.</p><p>Barton G.R., Sach T.H., Jenkinson C. et al. Do estimates of cost-utility based on the EQ-5D differ from those based on the mapping of utility scores? Health and Quality of Life Outcomes 2008;6:51.</p><p>Kobelt G. Thoughts on health economics in rheumatoid arthritis. Ann Rheum Dis 2007;66:iii35-iii39.</p><p>Thompson M., Leighton-Read J., Hutchings C. et al. The cost effectiveness of auronofin. J Rheumatol 1988;15:35-42.</p><p>Drummond M., Barberi M., Wang J. Analytic choices in economic models of treatments for rheumatoid arthritis: what makes a difference? Med Decis Making 2005;25:520-33.</p><p>Chen Y.F., Jobanputra P., Barton P. et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their .</p><p>Bansback N., Brennan A., Ghatneker O. Cost effectiveness of Adalimumab in the treatment of moderate to severe rheumatoid arthritis patients in Sweden. Ann Rheum Dis 2005;64:995-1002.</p><p>Chiou C.-F., Choi J., Reyes C.M. Cost-effectiveness analysis of biological treatments for rheumatoid arthritis. Exp Rev Pharmacoeconom Outcomes Res 2004;4:307-15.</p><p>Brennan A., Bansback N., Reynolds A., Conway P. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology 2004;43:62-72.</p><p>Bansback N., Brennan A., Ghatneker O. Cost effectiveness of Adalimumab in the treatment of moderate to severe rheumatoid arthritis patients in Sweden. Ann Rheum Dis 2005;64:995-1002.</p><p>Kobelt G., Lindgren P., Singh A., Klareskog L. Cost-effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial. Ann Rheum Dis 2005;64:1174-9.</p><p>Jobanputra P., Barton P., Bryan S., Burls A. The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 2002;6:21.</p><p>Welsing P.M.J., Severens J.L., Hartman M. et al. Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands. Arthr Rheum (Arthr Care Res) 2004;51:964-73.</p><p>Wong J.B., Singh G., Kavanaugh A. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am J Med 2002;113:400-8.</p><p>Kobelt G., Jonsson L., Young A., Eberhardt K. The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology 2003;42:326-35.</p></div><br />